Skip to content
A10185Assembly2023-2024 Session

Insurers Must Cover Brand Drugs

Official title

“Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug”

Sponsor Phara Souffrant ForrestAD-57Affects Finance
Status
In Assembly Committee
Insurance
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurance to cover brand-name prescription drugs at generic cost when generic versions are unavailable due to shortages.

Why it matters

  1. Protects patients from unexpected costs. When a generic drug is unavailable due to a recognized shortage, patients who rely on it for ongoing treatment won't face higher out-of-pocket expenses to access the brand-name version—helping those with chronic or previously diagnosed conditions avoid sudden financial strain.

  2. Ensures treatment continuity. By requiring insurance to cover brand-name drugs at the generic price during shortages, the bill reduces the risk of treatment interruptions, which can be particularly critical for people managing stable, long-term health issues.

  3. Limits insurer discretion during shortages. The bill mandates action based on FDA-recognized shortages and removes insurers’ ability to deny coverage or increase costs for brand-name drugs in these cases, standardizing patient protections across plans.

  4. Targets only off-patent drugs. The policy specifically applies to drugs that are no longer under patent, focusing relief on drugs where generics are expected to be available, rather than extending these provisions to newer, on-patent (and typically more expensive) medications.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Health insurers offering prescription drug coverage

    They would have to cover eligible off-patent brand-name drugs at the generic coverage level when a covered generic is unavailable because of an FDA-recognized supply issue and the dosage cannot be adjusted.

  • Insured patients affected by generic drug shortages

    Qualifying patients would receive brand-name coverage at the generic level until the supply issue is resolved and the drug is removed from the FDA shortage list.

  • Manufacturers of off-patent brand-name drugs

    Their eligible products would become required coverage alternatives for qualifying patients when covered generics are unavailable under the bill’s shortage conditions.

Headline styles

Insurers Must Cover Brand Drugs

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Phara Souffrant Forrest

Assembly Member · Assembly District 57

Rules

No co-sponsors yet.

History

  1. Referred to insurance

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

10185

IN ASSEMBLY

May 10, 2024

Introduced by COMMITTEE ON RULES -- (at request of M. of A. Forrest) -read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to substituting brand name prescription drugs in the case of a drug shortage

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 3242 of the insurance law is amended by adding a new subsection (d) to read as follows:

(d) (1) As used in this subsection:

(A) "Eligible prescription drug" means a prescription drug approved under 21 U.S.C. 355(c) that is not under patent.

(B) "Generic drug" means a drug that is approved pursuant to an application referencing an eligible prescription drug that is submitted under subsection (j) of Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355.

(C) "Supply issue" means a drug shortage or meaningful disruption as defined in 21 U.S.C. 356(c).

(2) In the event an AB-rated generic equivalent or interchangeable biological product for an eligible prescription drug is covered in an insurer's formulary and such generic drug equivalent is unavailable due to a supply issue which has been recognized by the federal food and drug administration pursuant to 21 U.S.C. 356e and the dosage cannot be adjusted, an insurer that delivers or issues for delivery in this state a policy that provides coverage for prescription drugs shall provide coverage for a brand name eligible prescription drug to an insured who is already receiving such prescription drug as a generic equivalent or has been diagnosed with or presented with a condition on or prior to the start of the plan year that is treated by such eligible prescription drug or is an eligible prescription drug that is or would be part of the insured's treatment regimen for such condition. Such brand name eligible prescription drug shall be covered at the same level of coverage as the generic drug in the insurer's formulary until such time as the supply issue is resolved and the drug has been removed from the federal food and drug administration's shortage list.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD15336-01-4

§ 2. Section 4329 of the insurance law is amended by adding a new subsection (d) to read as follows:

(d) (1) As used in this subsection:

(A) "Eligible prescription drug" means a prescription drug approved under 21 U.S.C. 355(c) that is not under patent.

(B) "Generic drug" means a drug that is approved pursuant to an application referencing an eligible prescription drug that is submitted under subsection (j) of Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355.

(C) "Supply issue" means a drug shortage or meaningful disruption as defined in 21 U.S.C. 356(c).

(2) In the event an AB-rated generic equivalent or interchangeable biological product for an eligible prescription drug is covered in an insurer's formulary and such generic drug equivalent is unavailable due to a supply issue which has been recognized by the federal food and drug administration pursuant to 21 U.S.C. 356e and the dosage cannot be adjusted, a corporation subject to the provisions of this article that issues a contract that provides coverage for prescription drugs shall provide coverage for a brand name eligible prescription drug to an insured who is already receiving such prescription drug as a generic equivalent or has been diagnosed with or presented with a condition on or prior to the start of the plan year that is treated by such eligible prescription drug or is an eligible prescription drug that is or would be part of the insured's treatment regimen for such condition. Such brand name eligible prescription drug shall be covered at the same level of coverage as the generic drug in the insurer's formulary until such time as the supply issue is resolved and the drug has been removed from the federal food and drug administration's shortage list.

§ 3. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.